Skip to main content

ArQule Value Stock - Dividend - Research Selection

ArQule

ISIN: US04269E1073, WKN: 903396

Market price date: 30.11.-0001
Market price: 0,00 USD




ArQule Fundamental data and company key figures of the share

Annual reports in USD
Key figures 09-03-2019
Cash flow
Net operating cash flow -12.976.000
Capital Expenditures -1
Free cash flow -12.976.000
Balance sheet
Total Equity 78.968.000
Liabilities & Shareholders equity 106.676.000
Income statement
Net income -15.482.000
Eps (diluted) -0,160
Diluted shares outstanding 96.762.500
Net sales/revenue 25.760.000

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolARQL
Market Capitalization1.935.250.048,00 USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internetwww.arqule.com


Description of the company

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.arqule.com